Business
BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma
BullFrog AI’s Patented Drug BF-223 Demonstrates Anti-Cancer Activity Against Glioblastoma in Established Animal Model GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"text","content":"BullFrog AI’s Patented Drug BF-223 Demonstrates Anti-Cancer Activity Against Glioblastoma in Established Animal Model\nGAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (\"BullFrog AI\" or the \"Company\"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced positive data in a preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for the treatment of glioblastoma. The study assessed the relative efficacy of BF-222, a novel formulation of mebendazole that has been evaluated in clinical trials, and BF-223, a novel prodrug of mebendazole with improved solubility and bioavailability relative to BF-222, compared with placebo in mice that had been implanted with tumor cells as a model for human glioblastoma. Animals treated with BF-223 had an average survival time of 27.9 days compared with 27.3 days for mice treated with BF-222 and 23.4 days for mice given placebo. Mice treated with BF-223 were administered 80% of the dose that mice treated with BF-222 received, and improved outcomes for both treatment groups were statistically significant compared to placebo. In addition, animals treated with equivalent doses of BF-222 and BF-223 showed comparable and significant reduction in tumor growth compared to control animals during the study. “This is the first study to demonstrate that BF-223, a novel mebendazole prodrug, has anti-cancer activity in animals,” said Vin Singh, Chairman and CEO of BullFrog AI. \"The data from this study, combined with BF-223’s improved properties, gives us confidence that BF-223 has potential to be an effective treatment in the fight against glioblastoma, a form of cancer for which there are few good treatment options. We are currently pursuing partnering opportunities for BF-222 and BF-223 with pharmaceutical companies and are confident that these data will assist in that effort.” About GlioblastomaGlioblastoma is a fast-growing and aggressive type of cancer that occurs in the brain or spinal cord. It is the most common malignant tumor of the central nervous system (CNS), accounting for nearly 50% of primary malignant tumors occurring in the CNS. Treatment options include surgery, radia...